INS and type 2 diabetes mellitus: Thus, whereas the use of metformin as an insulin-sensitizing and anti-hyperglycaemic drug has clear benefits in patients with T2D and reduces the impact of diabetes-relate premature aging of the vasculature while extending healthspan, it is less clear whether those benefits can be extended to non-T2D patients.